Core Insights - Emory University Hospital has become the first hospital to adopt the LIBERTY Endovascular Robotic System, aligning with its commitment to advancing interventional radiology [1][5] - LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision and reduce radiation exposure [2][6] - Microbot Medical is collaborating with Emory to establish an Endovascular Robotics Program, aiming to improve patient care in various peripheral intervention procedures [1][3] Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with LIBERTY being the first FDA-cleared single-use robotic solution [6] - The company emphasizes innovation and has a strong intellectual property portfolio, positioning itself as a leader in the future of endovascular care [6] Market Strategy - The limited market release of LIBERTY has commenced, with plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [2] - The adoption of LIBERTY is seen as a significant milestone in the surgical robotic space, reflecting years of dedication and progress by the Microbot team [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. Indicate by check whether the registrant: (1) has filed all reports required to be fi ...

Core Insights - Microbot Medical Inc. has announced the commercial availability of its LIBERTY® Endovascular Robotic System in the U.S. following FDA clearance, marking a significant milestone in the introduction of single-use robotic systems for peripheral endovascular procedures [1][2] - The Limited Market Release (LMR) will focus on high procedure volume regions to gather real-world insights and prepare for a Full Market Release (FMR) expected at the Society of Interventional Radiology meeting in April 2026 [1][2] Company Developments - The company has established a core commercial team and secured a third-party logistics partner to support the LMR of LIBERTY® [2] - Positive feedback from physicians and hospital administrators has validated the decision to proceed with the limited market release [1][2] Product Overview - LIBERTY® is the first FDA cleared single-use, remotely operated robotic system designed for precision, efficiency, and safety in endovascular procedures [3] - The product is backed by a strong intellectual property portfolio and a commitment to innovation, positioning Microbot Medical as a leader in the endovascular care market [3]

Core Insights - Microbot Medical Inc. is set to exhibit its LIBERTY Endovascular Robotic System at the upcoming Symposium on Clinical Interventional Oncology, marking its first commercial presence post-FDA clearance [1][2] - The company has completed the recruitment of its commercial leadership team in preparation for the limited market launch of the LIBERTY System, expected in Q4 of this year [2][6] Company Developments - The LIBERTY System will be showcased at booth 208, where interventional oncologists can schedule live hands-on demonstrations [2] - Justin Bourne has joined as Regional Sales Director, bringing 20 years of experience in sales leadership within the healthcare industry, previously at Boston Scientific [3] - Dani Kulp has been appointed as Sales Training Director, with over 15 years of experience in medical education and sales training, focusing on endovascular therapies [4] - Xiomara Ortiz has taken on the role of Marketing Communications Manager, leveraging her extensive experience in digital marketing and brand strategy to enhance the company's brand presence [5] Strategic Outlook - The company has secured a logistics partner and is preparing for the limited market launch of the LIBERTY System, indicating strong momentum since receiving FDA clearance [6] - The addition of key commercial team members is aimed at building a solid foundation for both immediate launch plans and long-term commercial strategy [6] Company Background - Microbot Medical Inc. focuses on transforming endovascular procedures through advanced robotic technology, with the LIBERTY System being the first single-use, remotely operated robotic solution designed for precision and safety [7]

Core Insights - Microbot Medical Inc. is set to launch its LIBERTY Endovascular Robotic System in Q4 2025, with a broader release planned for April 2026 during a major conference [1][4] Group 1: Company Overview - Microbot Medical Inc. specializes in innovative medical devices, focusing on transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and safety [4] Group 2: Partnership and Logistics - The company has partnered with a U.S.-based third-party logistics (3PL) provider to support the commercialization of the LIBERTY System, ensuring effective inventory management and customer support [1][2] - The 3PL provider specializes in the medical device industry, allowing the company to leverage its proximity to key markets and maintain inventory in a climate-controlled warehouse [2] Group 3: Operational Strategy - The partnership with an established logistics provider is expected to enhance the company's go-to-market initiatives, making the commercial launch of LIBERTY more efficient [3]

Core Points - Microbot Medical Inc. announced the third and final closing of its preferred investment options, resulting in the issuance of 13,989,115 shares of common stock [1][4] - The total gross proceeds from the three closings amounted to approximately $29.2 million, with potential additional proceeds of about $63 million from the exercise of short-term preferred investment options [4] Group 1: Investment Details - The first closing generated approximately $25.2 million from the exercise of options for 12,064,627 shares at prices ranging from $1.50 to $2.13 per share [2][4] - The second closing brought in approximately $1.2 million for 600,000 shares at an exercise price of $2.10 per share [2][4] - The third closing resulted in approximately $2.8 million for 1,324,488 shares at an exercise price of $2.10 per share [2][4] Group 2: Future Plans and Use of Proceeds - The company plans to utilize the net proceeds for the development, commercialization, and regulatory activities of its LIBERTY Robotic System, potential acquisitions, and general corporate purposes [4] - The new short-term series J preferred investment options will have an exercise price of $4.50 per share and will be exercisable six months after issuance [2][4] Group 3: Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY Endovascular Robotic System being a key product [7][8] - The company is backed by a strong intellectual property portfolio and is committed to innovation in endovascular care [8]

Core Insights - Microbot Medical Inc. has received its first patent in Japan for the LIBERTY® Endovascular Robotic System, enhancing its intellectual property portfolio [1] - The U.S. FDA granted marketing clearance for the LIBERTY® System on September 8, 2025, prompting the company to accelerate its commercial launch plans targeting 2.5 million peripheral endovascular procedures annually in the U.S. [2] - The company is focusing on the U.S. market while exploring opportunities in other global markets, particularly Japan, which may expedite local approval and adoption of its technology [3] Company Overview - Microbot Medical Inc. is a medical device company specializing in advanced robotic technology aimed at transforming endovascular procedures [3] - The LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and provider safety [3] - The company is committed to innovation and has a strong intellectual property portfolio to support its growth [3]

Core Viewpoint - Microbot Medical Inc. (MBOT) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending December 2025, Microbot Medical is expected to earn -$0.30 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 6.3% over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places Microbot Medical in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Core Insights - Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System, marking a significant milestone for the company in the commercialization of this innovative medical device [2][3] - The CEO, Harel Gadot, will discuss the implications of this FDA clearance and the company's commercialization plans during a live interview on Benzinga All Access [1] Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with the LIBERTY® Endovascular Robotic System being the first single-use, remotely operated robotic solution designed for precision and efficiency [3] - The company is backed by a strong intellectual property portfolio and is committed to innovation in the field of endovascular care [3]

Group 1 - Microbot Medical Inc. (NASDAQ:MBOT) has experienced a significant decline, with a 6.93% drop in share price, closing at $3.09, amid concerns over potential dilution from a fundraising program worth $63 million [1][4]. - The company raised $25.2 million from an options exercise, covering 12.06 million shares at prices between $1.5 and $2.13 [2]. - A second offering is expected to close on October 15, with over 1.9 million shares anticipated to be exercised at $2.10 each, potentially raising around $4 million [3]. Group 2 - The net proceeds from the fundraising efforts are intended for the development, commercialization, and regulatory activities of the LIBERTY Robotic System, as well as for potential acquisitions, expansion of applications from its existing IP portfolio, and general corporate purposes [5].